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Dr Frank Sellke (Boston, Mass). Is there a physiologic correlate
to this or is this purely a pharmacologic manifestation?
Dr Lisle. At this point it is purely a pharmacologic manifesta-
tion, in that we don’t see many physiologic changes when we
give the drug. If we give it in a very high dose, it causes substantial
vasodilation and hypotension. The dose that we give has been pre-
viously tested in our laboratory and found to be the most effective
dose without the aforementioned side effects. We were unable to
measure pulmonary artery pressure in the rats, which is something
that we are currently working on.
Dr Sellke. You found a tremendous benefit to this drug. Is there
some cellular mechanism that would explain all these different find-
ings simultaneously?
Dr Lisle. ATL313 is a specific A2AR agonist that belongs to
a family of adenosine receptors (A1, A2A, A2B, and A3) that are
ubiquitous throughout most tissues and most specific to inflamma-
tory cells, endothelial cells, macrophages, T cells, and neutrophils,
and it is shown to be uniformly inhibitory in those cell lines. So it is
something that we have been able to show before, but never in this
model.
Dr Paul Kurlansky (Miami, Fla). I just wanted to pursue that
exact line of thought, because what you havemeasured is obviouslyThe Journal of Thoracic and Cdownstream from the impact that this receptor is having. I was won-
dering if you could give us a little bit of guidance as to exactly
where in the inflammatory cascade this receptor is acting. Is this be-
fore nuclear factor kappa beta? You have complement release vir-
tually immediately, and yet the downstream effect seems to be
ameliorated in several different areas. So I was wondering if you
could just mechanistically give us sort of a tour of where you think
this is working?
Dr Lisle. I think it is probably working in concert with a few dif-
ferent cell lines at a few different points in the inflammatory path-
way. Our laboratory has done somework that you will hear about in
a little while, so I don’t want to necessarily spoil the punch line, but
I think it certainly works on a whole host of those cell lines. I think
that there is a substantial inflammatory activation within the bypass
pump itself. I also think there is a marked reperfusion injury within
the lung after bypass, and my guess is that the drug is helping atten-
uate both of those inflammatory responses.
Dr Christopher Caldarone (Toronto, Ontario, Canada). The
slides went by kind of quick, but I think you said that there weren’t
any changes in terms of oxygenation and physiologic parameters of
the lung, which weakens your argument a little bit that these
changes are clinically relevant. Nevertheless, your data are impres-
sive. What plans do you have in terms of what you are going to do
with your model to perhaps change it so you could demonstrate
clinically relevant changes in the model?
It really is an elegant model, and for those of us who might con-
template setting up a rat bypass model, what was your learning
curve like and how technically difficult is it to get one of these stud-
ies to go from start to finish?
Dr Lisle. This study is a compilation of about 2 years’ worth of
work for me in Dr Kron’s laboratory. The learning curve was sub-
stantially steep, but once you master it, things seem to become a lot
easier; at least I’d like to think so.
Dr Caldarone. I think that is the case with all science.
Dr Lisle. To answer your second question, the majority of the
animals we bypass go on to survive. Postoperatively, they are ex-
traordinarily hard to keep alive, and they require intense care
once they are extubated. We don’t see a lot of changes in oxygen-
ation initially, but my guess is that if we took them out further, more
than 90 minutes, we would see more significant changes in terms of
oxygenation and so forth. The direction we are heading right now is
to look at the effects of ventilation during bypass and then see if we
can figure out how this inflammatory response fits into the picture
of ischemia-reperfusion injury with other organ systems. The hy-
pothesis that we are going on now is that the lung is the centerpiece
of this whole inflammatory cascade within the body, resulting in
a systemic inflammatory response syndrome because it is relatively
ischemic with the cessation of pulmonary artery blood flow relative
to the rest of the organs in the body.
Dr William Smythe (Temple, Tex). We have a surgeon in my
department that has been working for the last several years on gen-
eralized endothelial or microvascular dysfunction in shock states.
As you know, that is a whole body ischemia-reperfusion model
whereby animals either have septic or hemorrhagic shock, and there
is a generalized microvascular permeability issue. This process can
involve extrathoracic sites, such as the brain, kidneys, and other tis-
sues or organs, many of which have deleterious effects on patients
in the intensive care unit and may lead to patient morbidity andardiovascular Surgery c Volume 136, Number 5 1287
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Pmortality. Do you have any evidence that ATL313 works on micro-
vascular permeability states in other areas of the body besides the
lung specifically?
DrLisle.There certainly has been a host of literature published on
the subject with ATL313 and its effects on adhesion molecules like
P-selectin, for example.We haven’t been able to evaluate any of that
specifically, but it is certainly somewhere we could go in the future.
Dr Yoshiya Toyoda (Pittsburgh, Pa). In your program do you
use adenosine during lung transplantation or CPB, and if so,
how? Do you put it in the pump prime or give it directly to the lung?1288 The Journal of Thoracic and Cardiovascular SuDr Lisle.We haven’t started using adenosine or ATL clinically
at the University of Virginia for lung transplantation; however, it is
being studied presently in a phase III trial for cardiac imaging. I ex-
pect, coming down the pipeline within the next 12 months or so, we
will start to see a compound similar to ATL313 in phase II trials for
acute inflammation, but nothing at this point.
Dr Toyoda. At the University of Pittsburgh Medical Center, we
have been using adenosine clinically since 1997 or so. We admin-
ister it directly into the lung through the pulmonary artery with
good outcome against ischemia-reperfusion injury.rgery c November 2008
